Free Trial
LON:OXB

Oxford Biomedica (OXB) Share Price, News & Analysis

Oxford Biomedica logo
GBX 425 0.00 (0.00%)
(As of 12/24/2024 12:46 PM ET)

About Oxford Biomedica Stock (LON:OXB)

Key Stats

Today's Range
423.34
430
50-Day Range
363.50
445
52-Week Range
167
450
Volume
92,931 shs
Average Volume
200,085 shs
Market Capitalization
£447.78 million
P/E Ratio
N/A
Dividend Yield
4.57%
Price Target
GBX 433.33
Consensus Rating
Hold

Company Overview

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Receive OXB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter.

OXB Stock News Headlines

Oxford Biomedica Announces Total Voting Rights Update
Cackling Kamala hates this company
Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.
Oxford BioMedica Sees Shift in Voting Rights
See More Headlines

OXB Stock Analysis - Frequently Asked Questions

Oxford Biomedica's stock was trading at GBX 220 on January 1st, 2024. Since then, OXB stock has increased by 93.2% and is now trading at GBX 425.
View the best growth stocks for 2024 here
.

Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF) and Barclays (BARC).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
891
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 433.33
High Stock Price Target
GBX 740
Low Stock Price Target
GBX 180
Potential Upside/Downside
+2.0%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
£-142,020,000.00
Net Margins
-145.98%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£97.28 million
Cash Flow
GBX 141.36 per share
Book Value
GBX 63 per share

Miscellaneous

Free Float
N/A
Market Cap
£447.78 million
Optionable
Not Optionable
Beta
1.09
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (LON:OXB) was last updated on 12/25/2024 by MarketBeat.com Staff
From Our Partners